No Data
Shanghai Hile Bio-Technology (603718.SH): Director and General Manager Han Benyi intends to reduce his Shareholding by no more than 0.75 million shares.
Gelonghui, February 19丨Shanghai Hile Bio-Technology (603718.SH) announced that Mr. Han Benyi, Director and General Manager, intends to reduce his shareholding in the company through a centralized bidding trading method due to personal funding needs. The number of shares to be reduced will not exceed 750,000 shares, which is no more than 0.1140% of the company's total share capital, and no more than 25% of his holdings in the company. The aforementioned reduction plan will be conducted within three months after the fifteenth trading day from the disclosure date of this announcement, and the reduction price will be determined based on the market price at the time of implementation.
Health Check: How Prudently Does Shanghai Hile Bio-Technology (SHSE:603718) Use Debt?
Hailey Biotech: Hailey Biotech 2024 Annual Results Advance Announcement
Hailey Biotech 2024 Annual Results Advance Announcement
Shanghai Hile Bio-Technology (603718.SH): Expected net income in 2024 to increase by 154.49% to 186.3% year-on-year.
On January 23, Gelonghui reported that Shanghai Hile Bio-Technology (603718.SH) announced that, 1. According to preliminary calculations by the finance department, the net income attributable to the shareholders of the listed company for the year 2024 is expected to be between 160 million yuan and 180 million yuan, an increase of 97.129797 million yuan to 117.129797 million yuan compared to the same period last year, representing a year-on-year growth of 154.49% to 186.30%. 2. The net income attributable to the shareholders of the listed company, after deducting non-recurring gains and losses, is expected to be between 8.2 million yuan and 12 million yuan, a decrease of 3.621974 million yuan compared to the same period last year.
Shanghai Hile Bio-Technology (603718.SH): planning to adjust the subscription of shares in the Shanghai Runling M&A Fund.
On December 23, Gelonghui reported that Shanghai Hile Bio-Technology (603718.SH) announced that the company recently received a change notice from Wuxi Haoling Investment Management Partnership (Limited Partnership) (referred to as "Wuxi Haoling"), the general partner, executive managing partner, and fund manager of the Shanghai Runling M&A Fund. The total subscribed capital contribution of the Shanghai Runling M&A Fund is planned to be adjusted from 650 million RMB to 122.7 million RMB. Given that the Shanghai Runling M&A Fund is now entering the exit period, the changes are based on fluctuations in policies and regulations, market environment, industry cycles, and other factors, and according to the partnership agreement section 3.3.7.
More Unpleasant Surprises Could Be In Store For Shanghai Hile Bio-Technology Co., Ltd.'s (SHSE:603718) Shares After Tumbling 31%
